Core Viewpoint - Yisheng Biotechnology (01061) experienced a stock price increase of over 10%, currently trading at 5.94 HKD with a transaction volume of 9.3261 million HKD, following the announcement of a joint development licensing agreement with Shanghai Junshi Biosciences Co., Ltd. [1] Group 1: Company Developments - Yisheng Biotechnology announced a joint development licensing agreement with its wholly-owned subsidiaries and Shanghai Junshi Biosciences, granting exclusive rights for the licensed product [1] - The licensed product is a recombinant anti-VEGF humanized monoclonal antibody, intended for the treatment of exudative (wet) age-related macular degeneration (wet AMD) [1] - The biological product license application for the anti-VEGF ophthalmic injection (HLX04-O) has recently been accepted by the National Medical Products Administration (NMPA) of China [1] Group 2: Product Details - HLX04-O is developed based on Junshi's independently developed Hanbeitai (Bevacizumab injection), optimized for ophthalmic use while maintaining the active ingredient [1] - The new ophthalmic formulation is designed to meet the specific needs for treating wet AMD [1]
港股异动 亿胜生物科技(01061)涨超10% anti-VEGF眼用注射生物药品的生物制品许可申请已获受理